Join us at Lotte New York Palace Hotel,
from March 21-24, 2022.

Visit our API team to get valuable insights about the API industry and our products.

Our Team at DCAT

Dr. Rajeev rehani Budhdev

Executive vice president and head API - R&D
Karun Gaur

Vice president Sales & Marketing
Rajesh Sadanandan

Vice president Sales & Marketing

B Vivek

Executive Vice President and Global Head of Delivery and Project Management
Kalpesh Modi

Associate Vice President Sales and marketing
E Sreedhar

Executive Vice President & Head Global RA, PSAI.

About DCAT Week

DCAT Week is one of the most significant annual events for the pharmaceutical industry. It's held in New York City where firms involved in the Bio/Pharmaceutical manufacturing value chain participate and book meeting spaces to conduct confidential, strategic discussions with clients and suppliers. Throughout the week, DCAT volunteer committees and task groups organise unique and relevant educational sessions for DCAT members. Members also receive access to networking events, member lounges, and other activities that foster industry collaboration opportunities. foster industry collaboration opportunities.

Know More

About Us

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy's API business operates in a number of global markets, including the United States of America, Europe, India, Russia, and other CIS nations.

Sustainability

Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.